Keyphrases
Randomized Trial
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Toll-like Receptor 2 (TLR2)
100%
Chemoimmunotherapy
100%
Confidence Interval
75%
Hazard Ratio
75%
Chemotherapy
75%
Survival Benefit
75%
Cisplatin
75%
Paclitaxel
50%
4-cycle
50%
Computed Tomography
25%
Disease Progression
25%
Overall Survival
25%
Median Survival
25%
Response Rate
25%
Improved Survival
25%
Median Overall Survival
25%
First-line Therapy
25%
2-cycles
25%
Randomized Controlled Trial
25%
Radiologists
25%
Log-rank Test
25%
Intention-to-treat Analysis
25%
Subgroup Analysis
25%
Paclitaxel Chemotherapy
25%
Squamous Cell
25%
Platinum-based Chemotherapy
25%
Systemic Side Effects
25%
Taxanes
25%
Cell Subsets
25%
Response Evaluation Criteria in Solid Tumors (RECIST)
25%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Chemotherapy
100%
Toll Like Receptor 2
100%
Paclitaxel
60%
Cisplatin
60%
Overall Survival
40%
Solid Malignant Neoplasm
20%
Disease Exacerbation
20%
Adverse Event
20%
Randomized Controlled Trial
20%
Cancer Staging
20%
Immunology and Microbiology
Agonist
100%
Overall Survival
100%
TLR2
100%
Squamous Cell
50%
Cancer Staging
50%
Computer Assisted Tomography
50%
Neuroscience
Agonist
100%
TLR 2
100%
Paclitaxel
75%
Cisplatin
75%
Computed Tomography
25%
Randomized Controlled Trial
25%
Taxane
25%